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Abstract The CXC chemokine receptor CXCR4/fusion, a
major coreceptor for the T-cell line T-tropic (X4) HIV-1 virus,
plays a critical role in T-tropic virus fusion and entry into
permissive cells. In the present study, we describe the effects of
an antisense phosphorothioate oligodeoxyribonucleotide (anti-S-
ODN) on the inhibition of CXCR4 gene expression in X4 HIV-1
infected HeLa-CD4 cells, to find more efficacious therapeutic
possibilities for human immunodeficiency virus type 1 (HIV-1)
infection. The naked antisense phosphorothioate oligodeoxy-
ribonucleotide (anti-S-ODN-1), containing the AUG initiation
codon at the center of the oligodeoxyribonucleotide, showed a
slightly higher inhibitory effect on HIV-1 gag p24 production
among all sequences tested. We also examined the concomitant
use of a basic peptide transfection reagent, nucleosomal histone
proteins (RNP), for the delivery of the anti-S-ODN-1. The anti-
S-ODN-1 encapsulated with RNP had higher inhibitory effects
on p24 products than the naked anti-S-ODN-1. When the anti-S-
ODN-1 encapsulated with RNP was incubated with HeLa-CD4
cells, the surface levels of this chemokine receptor showed high
suppression, indicating sequence-specific inhibition. The activ-
ities of unmodified oligodeoxyribonucleotide are effectively
enhanced by using a basic peptide, RNP. ß 2001 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
HIV-1 requires coreceptor molecules in addition to CD4 for
entry and fusion into target cells [1^3]. These coreceptors in-
clude the chemokine receptors, which are 7-transmembrane
domain G-protein coupled receptors. Although the list of pos-
sible coreceptors is continuously expanding, the major core-
ceptors are CCR5 and CXCR4, which facilitate the cell entry
of the macrophage-tropic (R5 viruses, based on the new clas-
si¢cation) and X4 (appear late in the disease) strains of HIV-
1, respectively [1^6]. RANTES, macrophage in£ammatory
protein (MIP)-1K, and MIP-1L are ligands for CCR5 and
block R5 HIV-1 infection [7], whereas stromal cell-derived
factor-1 (SDF-1) is a ligand for CXCR4 and blocks X4 HIV-1
infection [8,9]. Chemokines, modi¢ed chemokines, peptides,
and non-peptide receptor antagonists or agonists have become
important agents for the treatment of HIV-1 infection
[7,10,11]. Recently, two groups have reported that the horse-
shoe crab blood cell-derived peptide, T22 [12], and the non-
peptide, TAK-779 [13], act as CXCR4 and CCR5 antagonists
that can inhibit infection by X4 and R5 HIV-1, respectively.
Furthermore, a hammer-head ribozyme and a DNA enzyme
can also inhibit the coreceptor CCR5 function [14,15]. Based
on these ¢ndings, we proposed that down-regulation of
CXCR4 expression by antisense oligodeoxyribonucleotides
(anti-ODNs) may be an e¡ective and harmless way to inhibit
HIV-1 infection [16]. The use of antisense ODNs as therapeu-
tic tools in modulating gene expression represents a newly
established strategy for treating diseases [17^21]. Such anti-
sense ODNs are designed to complement the respective target
mRNAs, whereby they inhibit the translation of the speci¢c
mRNA. The applications of antisense ODNs for anti-HIV-1
gene therapy are based on the use of antisense ODNs targeted
to viral transcripts [22^25].
In this study, we analyzed the down-regulation of the func-
tional expression of the HIV-1 coreceptor, CXCR4, by RNP
(basic peptide transfection reagent) [26,27] encapsulated anti-
sense phosphorothioate oligodeoxyribonucleotides (anti-S-
ODN-1^3), which contains the AUG initiation codon at its
center and the downstream coding region, close to the AUG
initiation codon.
2. Materials and methods
2.1. Antisense phosphorothioate (anti-S-) and phosphodiester (anti-O-)
oligodeoxyribonucleotides, and transfection reagents
The antisense sequence, including the initiation region of the
CXCR4 mRNA (MEDLINE, human mRNA for HM89), and its
sense and scrambled sequences, were tested in the present study.
The nucleotides within the initiation codon are underlined. S-ODNs,
FITC-labeled anti-S-ODN-1 (5P-labeled), and anti-O-ODN-1 were
purchased from KURABO Biomedical Co. (Japan). They were the
antisense S-ODN-1 and the antisense O-ODN-1 [5P-GATCCCCTC-
CATGGTAACCG-3P (anti-S-ODN-1 and anti-O-ODN-1)], comple-
mentary to bases 69^88 of the human CXCR4 mRNA, the sense S-
ODN-1 and the sense O-ODN-1 [5P-CGGTTACCATGGAGGG-
GATC-3P (sen-S-ODN-1 and sen-O-ODN-1)], corresponding to the
sequence of bases 69^88 of the human CXCR4 mRNA, and the
scrambled S-ODN-1 [5P-ATCGCCTAGCTACCTACGCG-3P (scr-S-
ODN-1)] with the same base composition as the antisense 1 target
(69^88 bases). The antisense S-ODN-2 [5P-GTGTATATACTGA-
TCCCCTC-3P (anti-S-ODN-2)], complementary to bases 80^99 of
the human CXCR4 mRNA, and the antisense S-ODN-3 [5P-TTA-
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TCTGAAGTGTATATACT-3P (anti-S-ODN-3)], complementary to
bases 89^108 of the human CXCR4 mRNA, were also synthesized.
The sequence of the FITC-labeled anti-S-ODN-1 was the same as
that of the antisense.
Our originally constructed peptide transfectant (named RNP: re-
constituted nucleosomal protein) was prepared with the nucleosomal
histone subunits: H2A, H2B, H3, and H4. Histone subunits were
purchased from Boehringer Mannheim (GmbH, Germany). The opti-
mal proportions for ionic complex formation between the peptide and
the ODNs were determined using a 20% denatured polyacrylamide gel
electrophoresis (PAGE) retardation system. It was necessary to mix
H2A (0.004 Wg) and H2B (0.004 Wg) in 20 mM phosphate bu¡er (pH
7.2) before the addition of any other subunit. Next, the antisense
ODN (1 Wg) was added to the solution. Then H3 (0.0047 Wg) was
added, followed by H4 (0.0034 Wg). This mixture was added to the
culture medium for the transfection of HeLa-CD4 cells with the S-
ODNs by the use of the RNP.
2.2. Cells and viruses
The HeLa-CD4 cell line (human cervical carcinoma) expressing
CXCR4 was grown in RPMI 1640 media supplemented with 10%
fetal bovine serum (FBS) (United Biotechnology), 50 units/ml penicil-
lin, and 50 units/ml streptomycin at 37‡C in a 5% CO2-gassed incu-
bator.
HIV-1 NL432 was produced by transfection of the proviral DNA
clone, pNL432, into COS cells. The supernatants were clari¢ed by
¢ltration, and the levels of p24 antigen, the core antigen of HIV-1,
were determined by ELISA. The amounts of viruses were expressed as
the concentrations of p24 antigen. The virus stocks were analyzed for
their p24 antigen levels and were stored at 380‡C until use.
2.3. Anti-HIV-1 activity of anti-S-ODNs and anti-O-ODN-1
Several concentrations of anti-S-ODNs and anti-O-ODN-1, as an
anti-HIV drug, were added to cultured HeLa-CD4 cells for 24 h in 24-
well plates (1U105 cells/ml/well). After 24 h of culture, the HeLa-CD4
cells were washed twice with fresh medium, and then were infected
with the HIV-1 NL432 virus (MOI: multiplicity of infection = 0.1) in
1 ml of medium at 37‡C and in a 5% CO2 atmosphere for 3 h. The
cells were washed twice with fresh medium to remove the residual
virions, gently resuspended in fresh medium with 10% FBS, and cul-
tured for 24 h. Anti-HIV activity was determined by measuring the
amount of p24 antigen in the supernatant, using an HIV-1 p24 ELI-
SA.
2.4. Staining of treated HeLa-CD4 cells
To down-regulate CXCR4 expression, the naked and encapsulated
anti-S-ODN-1 was incubated for 24 h with washed HeLa-CD4 cells
(1U106 cells/2 ml/well) that had been inoculated 24 h previously and
maintained as described above. After the anti-S-ODN-1 treatment, the
cells were scraped, washed twice in cold PBS, and resuspended in
PBS. After centrifugation for 2 min at 2000 rpm, the cells were stained
with monoclonal antibodies speci¢c for human CXCR4 (12G5 mouse
IgG2a) (Pharmingen), and then were incubated with secondary FITC-
labeled antibodies (rat anti-mouse IgG2a: FITC) (Serotec). As a con-
trol (data not shown), the cells were stained with monoclonal anti-
bodies speci¢c for CD4 (conjugated to phycoerythrin, PE) (Dako
Japan Co., Ltd.). After staining, the cells were washed and resus-
pended in 0.5% HCHO/PBS.
2.5. Flow cytometry and analysis
CXCR4 expression in stained cells was analyzed by £ow cytometry
with a FACSCalibur (Becton Dickinson) £ow cytometer and the Cell
Quest software (Becton Dickinson). For each sample, 30 000 total
events were analyzed, with sequential gating of HeLa-CD4 cells.
2.6. Intracellular localization of FITC-labeled anti-S-ODN-1 in
HeLa-CD4 cells
HeLa-CD4 cells were incubated in RPMI 1640 at 37‡C and in a 5%
CO2 atmosphere for 24 h. The cultures, in 6-well plates (1U106 cells/2
ml/well), were washed twice with PBS, and then 5 WM FITC-labeled
anti-S-ODN-1 was added and the cultures were incubated for 4 h as
above. The cells were washed twice with PBS, scraped o¡, resus-
pended in 0.5% HCHO/PBS and 0.5% glycerol/PBS, and observed
by laser-assisted confocal microscopy (Molecular Dynamics, Multi-
Probe 2001).
3. Results and discussion
3.1. Sequence-speci¢c inhibition of the CXCR4 chemokine
receptor function by naked antisense phosphorothioate
oligodeoxyribonucleotides (anti-S-ODN-1^3) in
HeLa-CD4 cells
Antisense oligonucleotides have become widely used in re-
search into the speci¢c inhibition of gene expression. They are
now being investigated as possible therapeutic agents. Such
oligodeoxyribonucleotides may be designed to complement a
region of a particular gene or messenger RNA. We selected an
antisense oligodeoxyribonucleotide sequence, including the in-
itiation codon. The translation initiation site was chosen as a
target site in several other mRNAs. The HeLa-CD4 cells were
used as the target cells, since they were infected with the X4
HIV-1 NL432.
It was reported previously that we evaluated the inhibitory
e¡ects on the functional expression of the CXCR4 receptor in
HeLa-CD4 cells using the naked antisense phosphorothioate
oligodeoxyribonucleotide (anti-S-ODN-1) containing the
AUG initiation codon at its center [16]. The anti-S-ODN-1
was directly added to the cultured cells, and then the cells
were incubated at 37‡C. The anti-S-ODN-1 had an inhibitory
e¡ect on the HIV-1 gag p24 antigen at a highest concentration
of 10 WM. Two di¡erent control oligodeoxyribonucleotides
were prepared, the sen-S-ODN-1 and scr-S-ODN-1 sequences,
with the same base composition as that of the anti-S-ODN-1
target. For control oligodeoxyribonucleotide sequences, sen-S-
ODN-1 and scr-S-ODN-1, we could not detect any inhibitory
e¡ects on the HIV-1 gag p24 antigen at the highest concen-
tration of 10 WM.
Next, we also synthesized the antisense phosphorothioate
oligodeoxyribonucleotides (anti-S-ODN-2 and anti-S-ODN-
3) complementary to the downstream coding region, close to
the AUG initiation codon of the CXCR4 mRNA (see Section
2). However, they showed lower anti-HIV-1 activities than
that of the anti-S-ODN-1 (Fig. 1). The anti-S-ODN-1 was
the most potent among the antisense S-ODNs for the inhibi-
tion of the HIV-1 gag p24 antigen production. On the other
hand, the sequence-speci¢c down-regulation of surface
CXCR4 expression on HeLa-CD4 cells with the anti-S-
ODN-1 was detected by £ow cytometry using the monoclonal
Fig. 1. Sequence-speci¢c inhibition of HIV-1 infection in HeLa-CD4
cells by the naked antisense phosphorothioate oligodeoxyribonucleo-
tides (anti-S-ODN-1^3). HeLa-CD4 cells were infected with HIV-1
NL432 in the presence or absence of di¡erent concentrations of the
naked antisense phosphorothioate oligodeoxyribonucleotides (anti-S-
ODN-1^3). Aliquots of the culture supernatant were assayed for
HIV-1 gag p24 content by ELISA. The experiment reported is rep-
resentative of a set of three di¡erent experiments.
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anti-CXCR4 antibody (12G5 mouse IgG2a) [16]. The anti-S-
ODN-1 had an inhibitory e¡ect, causing more than 50%
inhibition of surface CXCR4 expression at the highest con-
centration of 10 WM. On the other hand, with the control
sequence, the sen-S-ODN-1, we could not detect any
inhibitory e¡ects on the surface CXCR4 expression in
HeLa-CD4 cells. These results suggest that the down-regula-
tion of CXCR4 expression by the anti-S-ODN-1 may block
HIV-1 entry into human cells. Based on these results, the
following antisense experiments were performed using the
anti-S-ODN-1.
3.2. Confocal microscopic observation of the uptake of
encapsulated and naked FITC anti-S-ODN-1 in
HeLa-CD4 cells
Antisense ODNs have been used as antisense inhibitors of
gene expression in various culture systems and are considered
to be potential therapeutic agents against cancer and viral
infectious diseases. In order to exert any of these e¡ects, the
anti-ODNs must enter the cytoplasmic and nuclear compart-
ments of the cells. The problem in the use of antisense ODNs
is that the cellular uptake of anti-ODNs is ine⁄cient [28,29].
The use of various enhancers to increase the intracellular ac-
cumulation of the anti-S-ODNs has largely solved this prob-
lem, and has greatly facilitated their use as research tools in
vitro. Many cellular uptake enhancers have been reported,
including cationic lipids, liposomes, peptides, dendrimers,
polycations, cholesterol conjugates, and electroporation. One
of the most commonly used enhancers is a mixture of neutral
and cationic lipids [30^35].
We analyzed the e⁄ciency of the delivery of the encapsu-
lated FITC-labeled anti-S-ODN-1 with a basic peptide trans-
fection reagent, nucleosomal histone protein (RNP) [26,27],
into HeLa-CD4 cells using laser-assisted confocal microscopy.
The nucleosomal histone proteins, which are known as basic
proteins, possess nuclear localization signals and helical do-
mains. The RNP was prepared as indicated in Section 2. As
shown in Fig. 2B, the FITC-labeled anti-S-ODN-1 with RNP
revealing a major portion is localized within the nucleus and
cytoplasms within HeLa-CD4 cells. In contrast to this obser-
vation, little £uorescent signals were observed either in the
endosomes and cytoplasms of HeLa-CD4 cells treated with
the naked FITC-labeled anti-S-ODN-1 (Fig. 2A). However,
no cell surface-bound S-ODNs were detected. Thus, in the
presence of the RNP transfection reagent, the anti-S-ODNs
¢rst enter the cytoplasm and then quickly accumulate in the
nucleus. The localization of anti-S-ODN-1 with the nucleus
has implications for the mechanism of action of this and other
antisense phosphorothioate constructs. The uptake of anti-
sense S-ODNs was greatly enhanced by RNP encapsulation.
These results prove that the FITC-labeled anti-S-ODN-1 en-
capsulated with RNP penetrates the HeLa-CD4 cells, and
then the anti-S-ODN can hybridize to the target sequence in
the mRNA.
Fig. 2. Intracellular localization of FITC-labeled anti-S-ODN-1 delivered by a basic peptide transfection reagent, nucleosomal histone proteins
(RNP) into HeLa-CD4 cells, observed by laser-assisted confocal microscopy. A: FITC-labeled anti-S-ODN-1 alone. B: FITC-labeled anti-S-
ODN-1 encapsulated with RNP. C: HeLa-CD4 cells alone. The cells were washed twice with PBS, scraped o¡, resuspended in 0.5% HCHO/
PBS and 0.5% glycerol/PBS, and observed by laser-assisted confocal microscopy.
Fig. 3. Sequence-speci¢c inhibition of the CXCR4 chemokine recep-
tor function by the anti-S-ODN-1 encapsulated with RNP in HeLa-
CD4 cells. HeLa-CD4 cells were incubated with 0.1, 1, and 10 WM
of the phosphorothioate oligodeoxyribonucleotides (anti-S-ODN-1
and sen-S-ODN-1) encapsulated with RNP. The surface CXCR4 ex-
pression on HeLa-CD4 cells was detected by £ow cytometry using
the monoclonal anti-CXCR4 antibody (12G5 mouse IgG2a). The
experiment reported is representative of a set of three di¡erent ex-
periments.
FEBS 24471 9-1-01 Cyaan Magenta Geel Zwart
A. Kusunoki et al./FEBS Letters 488 (2001) 64^6866
3.3. Sequence-speci¢c inhibition of the CXCR4 chemokine
receptor function by the anti-S-ODN-1 encapsulated with
RNP in HeLa-CD4 cells
Synthetic antisense phosphorothioate oligodeoxyribonucleo-
tides (anti-S-ODNs) have been widely used as tools for the
speci¢c inhibition of gene expression. They are considered to
be a potential new generation of drugs. Antisense ODNs can
inhibit various viral pathogens and regulate speci¢c gene ex-
pression by inhibiting transcription or translation through their
complementary interactions with targeted genetic segments.
However, there are some problems with the use of ODNs, in
that cells are not very permeable to ODNs, and the ODNs are
not stable for in vivo applications. Thus, transport and intra-
cellular delivery are important and fundamental considerations
when developing an e¡ective ODN-based therapy.
We evaluated the inhibition of the functional expression of
the CXCR4 receptor gene using several concentrations of the
anti-S-ODN-1 encapsulated with a basic peptide transfection
reagent, nucleosomal histone proteins (RNP). The RNP was
prepared as indicated in Section 2. The surface CXCR4 ex-
pression on HeLa-CD4 cells was detected by £ow cytometry
using the monoclonal anti-CXCR4 antibody (12G5 mouse
IgG2a). The anti-S-ODN-1 encapsulated with RNP showed
80% inhibition of the surface CXCR4 expression on HeLa-
CD4 cells at a 1 WM concentration, whereas at the highest
concentration of 10 WM, it had an inhibitory e¡ect similar to
that of the 1 WM concentration (Fig. 3). However, at the lower
concentration of 0.1 WM, the anti-S-ODN-1 encapsulated with
RNP slightly suppressed the CXCR4 expression. In contrast,
almost no inhibition was observed when the reaction was
carried out using the control ODN, sen-S-ODN-1, instead
of the anti-S-ODN-1, at concentrations of 0.1, 1, and 10
WM. For p24 assaying in HeLa-CD4 cells, the anti-S-ODN-1
encapsulated with RNP had a higher inhibitory e¡ect (70%) at
the 1 WM concentration [16]. However, naked anti-S-ODN-1
showed lower anti-HIV-1 activity (11%). For the control se-
quence, sen-S-ODN-1, we could not detect any inhibitory
e¡ects on the HIV-1 gag p24 antigen expression at a con-
centration of 1 WM. Of particular interest is the RNP
encapsulated antisense phosphodiester oligodeoxyribonucleo-
tide (anti-O-ODN-1), which was found to have an inhibitory
e¡ect on the HIV-1 gag p24 antigen expression of same order
as those for the RNP encapsulated antisense phosphoro-
thioate oligodeoxyribonucleotide (anti-S-ODN-1), probably
due mainly to their relative nuclease resistance in culture me-
dium (Fig. 4) [36,37]. For the control sequence, the sen-O-
ODN-1, we could not detect any inhibitory e¡ects on the
HIV-1 gag p24 antigen expression at a concentration of
1 WM. These results suggest that the anti-ODNs encapsulated
with RNP conferred sequence-speci¢c inhibition. The use of
an RNP transfection reagent confers a signi¢cant advantage
over the use of the anti-ODNs alone for the delivery of the
anti-ODNs into HeLa-CD4 cells. Furthermore, the antisense
ODNs encapsulated with RNP might explain the enhanced
antisense activity.
In conclusion, anti-S-ODN-1, containing an AUG initiation
codon at the center of the oligodeoxyribonucleotide targeted
to the CXCR4 mRNA, showed the greatest inhibitory e¡ects
among the S-ODNs on HIV-1 gag p24 antigen production
and also on CXCR4 expression in HeLa-CD4 cells, consistent
with the assumption that this region is important and acces-
sible. The use of the cationic peptide, RNP, provides a simple
and e⁄cient method for the successful intracellular delivery of
the oligodeoxyribonucleotides. The anti-S-ODNs encapsu-
lated with RNP exhibited higher inhibitory activities than
the naked anti-S-ODNs, and showed sequence-speci¢c inhibi-
tion. The activities of unmodi¢ed oligodeoxyribonucleotides
are e¡ectively enhanced by using a cationic peptide, RNP.
Consequently, the encapsulated anti-S-ODN-1 may be useful
to block HIV-1 entry into human cells.
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